Noetik Inc. has closed an oversubscribed $14 million seed financing round. The company has built a multimodal tissue profiling platform that combines self-supervised learning with spatial biology to tackle problems in cancer immunology.

Xtalpi Inc. and Parthenon Therapeutics Inc. (now known as Incendia Therapeutics Inc.) have entered into a collaboration to discover novel therapeutic antibodies for the treatment of solid tumors.

Serengen GmbH and Deargen Inc. have established a collaboration to accelerate the drug discovery process by bringing together Serengen’s novel DNA encoded library (DEL) technology with Deargen’s artificial intelligence (AI)-driven drug discovery platform, Deardti.

3Z ehf and Biotx.ai AG have established a strategic partnership to help advance the development of drugs for attention deficit hyperactivity disorder (ADHD).

Artificial intelligence (AI) continues to entice. On the exhibition floor at the 2023 Congress of the European Academy of Neurology, one company’s booth featured “Mindart” technology. A passersby could answer a short series of prompts, and get a unique image based on the input made by generative AI. Entertainment aside, medically speaking, AI applications “are still research,” Riccardo Soffietti told his audience at one of several sessions devoted to AI. “But obviously, research is the future.”

Poolbeg Pharma plc has announced the discovery of multiple influenza drug targets through an artificial intelligence (AI)-led program.

Delta4 GmbH has announced the identification of a potential new therapeutic option for the treatment of focal segmental glomerulosclerosis (FSGS).